Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) CEO Richard J. Daly Sells 17,323 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Free Report) CEO Richard J. Daly sold 17,323 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $15.97, for a total transaction of $276,648.31. Following the transaction, the chief executive officer now owns 234,824 shares of the company’s stock, valued at $3,750,139.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $15.76 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $11.48 and a fifty-two week high of $17.50. The stock has a market cap of $1.86 billion, a PE ratio of 29.19, a price-to-earnings-growth ratio of 1.36 and a beta of 0.73. The firm’s 50-day simple moving average is $15.66 and its 200 day simple moving average is $15.22.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, hitting the consensus estimate of $0.31. The business had revenue of $98.51 million for the quarter, compared to analysts’ expectations of $97.24 million. Catalyst Pharmaceuticals had a net margin of 15.83% and a return on equity of 25.08%. As a group, analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.78 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Oppenheimer reiterated an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday. Citigroup assumed coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 14th. They set a “buy” rating and a $27.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $34.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. StockNews.com cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Finally, Bank of America started coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 7th. They set a “buy” rating and a $23.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $26.71.

Get Our Latest Research Report on Catalyst Pharmaceuticals

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust purchased a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $31,000. GAMMA Investing LLC boosted its stake in Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 819 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 306.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 3,829 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Catalyst Pharmaceuticals by 84.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 2,833 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Catalyst Pharmaceuticals in the first quarter valued at about $154,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

(Get Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Recommended Stories

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.